Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for Electromed, Inc. (NYSE American: ELMD), a Minnesota-based medical device company that develops, manufactures, and sells airway clearance therapy products such as the SmartVest® Airway Clearance System. These regulatory documents provide detailed insight into Electromed’s financial condition, governance, and material corporate events.
Through periodic reports like the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, Electromed discloses information on its revenues from direct homecare and non-homecare markets, gross profit, operating expenses, research and development, and net income. These filings also describe risk factors related to reimbursement, regulatory compliance, competition, component supply, and other aspects of operating in the medical device industry.
Current Reports on Form 8-K document specific events, such as the announcement of quarterly and annual financial results, updates to investor presentations, approval of share repurchase authorizations, and the entry into a Credit Agreement with BMO Bank N.A. that provides a senior secured revolving credit facility. Other 8-K filings cover shareholder meeting results, including director elections, auditor ratification, and advisory votes on executive compensation.
The Definitive Proxy Statement on Form DEF 14A offers additional detail on corporate governance, board composition, executive and director compensation, equity compensation plans, and the procedures for the annual meeting of shareholders, which Electromed has conducted as a virtual meeting via webcast.
On Stock Titan, Electromed’s SEC filings are available with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as revenue drivers, capital allocation decisions, credit facility terms, and governance matters. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, DEF 14A, and related filings, as well as any insider transaction reports on Form 4, are accessible with clear explanations of their significance for ELMD shareholders and analysts.
Electromed, Inc. entered into a new Credit Agreement with BMO Bank N.A., providing a senior secured revolving credit facility of $10,000,000. The facility matures on December 16, 2026, and any borrowings will bear interest at one-month Term SOFR plus 1.75%, payable monthly.
The company granted a first-priority security interest in substantially all existing and future assets and agreed to customary covenants, indemnities, and events of default. While amounts are outstanding, Electromed must maintain a minimum Fixed Charge Coverage Ratio of at least 1.20x and a Total Funded Debt to EBITDA ratio of not more than 2.50x, calculated quarterly on a rolling four-quarter basis. Proceeds may be used for capital expenditures, working capital, and general corporate purposes, and the prior credit facility with Choice Financial Group was terminated.
Electromed, Inc. reported an insider equity award for one of its directors. On 12/01/2025, the director acquired 3,000 shares of common stock as an award of restricted stock at a stated price of $0, reflecting a grant rather than an open-market purchase. Following this transaction, the director beneficially owns 15,000 shares directly.
The restricted stock is scheduled to vest on June 1, 2026, unless it is accelerated or terminated earlier under its terms, meaning the director’s ability to fully realize the award depends on continued satisfaction of those conditions.
Electromed, Inc. reported an insider equity grant to a director. A board member filed a Form 4 showing an acquisition of 3,000 shares of Electromed common stock on 12/01/2025 at a stated price of $0. These shares are described as restricted stock scheduled to vest on June 1, 2026, unless earlier accelerated or terminated under their terms.
After this transaction, the director beneficially owned 38,817 shares of Electromed common stock directly and 1,500 shares indirectly through Liberty Capital, LP. The filing notes that the reporting person disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest in them.
Electromed, Inc. reported a Form 4 insider transaction for a company director. On 12/01/2025, the director acquired 3,000 shares of common stock, coded as an "A" transaction, at a reported price of $0, indicating a grant rather than an open-market purchase. These shares are described as restricted stock scheduled to vest on June 1, 2026, unless earlier accelerated or terminated under their terms.
Following this grant, the director beneficially owned 21,000 shares of Electromed common stock in direct form. The filing is made by a single reporting person in the capacity of Director of Electromed.
Electromed, Inc. reported that one of its directors acquired 3,000 shares of common stock as a restricted stock award on December 1, 2025 at a stated price of $0 per share. After this award, the director beneficially owns 15,000 shares of Electromed common stock in direct ownership form. The restricted stock is scheduled to vest on June 1, 2026, unless vesting is accelerated or the award is terminated under its terms, meaning the director must remain eligible through that date to receive the shares without restrictions.
Electromed, Inc. reported an insider stock award for one of its directors. On 12/01/2025, the director acquired 3,000 shares of common stock, described as restricted stock, at a price of $0 per share. After this grant, the director beneficially owns 35,622 shares of Electromed common stock.
The restricted shares are scheduled to vest on June 1, 2026, unless they are accelerated or terminated under their terms. This filing is a routine disclosure of insider equity compensation and does not involve a public offering or sale of shares into the market.
Electromed, Inc. director and 10% owner received additional equity in the company. On December 1, 2025, the reporting person acquired 3,000 shares of Electromed common stock as restricted stock at a stated price of $0. After this grant, the reporting person holds 12,000 shares directly.
The filing also reports 270,367 shares held indirectly through Summers Value Fund LP. An explanation notes that this balance includes 100 additional shares identified through a routine reconciliation of ownership records. The 3,000 restricted shares are scheduled to vest on June 1, 2026, unless vesting is accelerated or the award is terminated under its terms.
Electromed, Inc. (ELMD) reported the results of its annual shareholder meeting held on November 14, 2025. Shareholders elected all nominated directors to the Board, with each nominee receiving substantially more votes "for" than "withheld." Other management proposals also received strong support, including the advisory vote approving executive compensation. Shareholders additionally voted on how often they want an advisory vote on executive pay, and the Board determined, based on these results, to continue including this vote in the proxy materials on an annual basis. These outcomes keep the company’s governance structure and executive pay practices largely unchanged.
Electromed, Inc. (ELMD) reported stronger Q1 FY2026 results. Net revenues rose 15.1% to $16,887,000, led by homecare ($14,889,000), hospital ($1,047,000), and homecare distributors ($829,000). Gross profit was $13,197,000 at 78.1% of revenue. Operating income increased to $2,670,000 and net income grew 44.9% to $2,136,000, with diluted EPS of $0.25.
SG&A was $10,286,000, reflecting investments in sales, travel, and marketing; R&D was $241,000. Cash and cash equivalents were $14,113,000, and total shareholders’ equity reached $44,745,000. Operating cash flow was $169,000 after seasonal compensation payouts and inventory build; capital expenditures were $252,000. The company has a $2,500,000 revolving credit facility with no borrowings outstanding.
Capital returns: A stock repurchase authorization of up to $10,000,000 was approved on September 9, 2025; during the quarter, 40,848 shares were repurchased for $1,003,000 at an average of $24.57. Shares outstanding were 8,340,538 as of November 5, 2025. Management cites a working capital position of approximately $35,800,000 and states liquidity is sufficient for the next twelve months.
Electromed, Inc. (ELMD) furnished an 8-K announcing it issued a press release with financial results for the first quarter ended September 30, 2025, and updated its investor presentation. The press release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2.
The company noted that the information, including Exhibits 99.1 and 99.2, is being furnished and not filed under the Exchange Act, and will not be incorporated by reference into a Securities Act registration statement except as specifically referenced.
FAQ
What is the current stock price of Electromed (ELMD)?
What is the market cap of Electromed (ELMD)?
